4.4 Article

IKZF1 deletion is an independent predictor of outcome in pediatric acute lymphoblastic leukemia treated according to the ALL-BFM 2000 protocol

期刊

HAEMATOLOGICA
卷 98, 期 3, 页码 428-432

出版社

FERRATA STORTI FOUNDATION
DOI: 10.3324/haematol.2011.056135

关键词

-

资金

  1. Federal Ministry of Education and Research (BMBF
  2. NGFN) [01GS0442]
  3. Deutsche Krebshilfe
  4. Madeleine Schickedanz Kinderkrebs-Stiftung

向作者/读者索取更多资源

IKZF1 gene deletions have been associated with a poor outcome in pediatric precursor B-cell acute lymphoblastic leukemia. To assess the prognostic relevance of IKZF1 deletions for patients treated on Berlin-Frankfurt-Munster Study Group trial ALL-BFM 2000, we screened 694 diagnostic acute lymphoblastic leukemia samples by Multiplex Ligation-dependent Probe Amplification. Patients whose leukemic cells bore IKZF1 deletions had a lower 5-year event-free survival (0.69 +/- 0.05 vs. 0.85 +/- 0.01; P<0.0001) compared to those without, mainly due to a higher cumulative incidence of relapses (0.21 +/- 0.04 vs. 0.10 +/- 0.01; P=0.001). Although IKZF1 deletions were significantly associated with the P2RY8-CRLF2 rearrangement, their prognostic value was found to be independent from this association. Thus, IKZF1 deletion is an independent predictor of treatment outcome and a strong candidate marker for integration in future treatment stratification strategies on ALL-BFM protocols. Clinicaltrials.gov identifier: NCT00430118

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.4
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据